Acumen Pharmaceuticals Inc’s recently made public that its CFO & Chief Business Officer Zuga Matt unloaded Company’s shares for reported $49633.0 on Jan 23 ’25. In the deal valued at $1.72 per share,28,902 shares were sold. As a result of this transaction, Zuga Matt now holds 231,744 shares worth roughly $0.28 million.
Then, Zuga Matt sold 4,364 shares, generating $6,986 in total proceeds. Upon selling the shares at $1.60, the CFO & Chief Business Officer now owns 260,646 shares.
Before that, OConnell Daniel Joseph sold 12,619 shares. Acumen Pharmaceuticals Inc shares valued at $20,102 were divested by the Chief Executive Officer at a price of $1.59 per share. As a result of the transaction, OConnell Daniel Joseph now holds 667,488 shares, worth roughly $0.81 million.
Citigroup initiated its Acumen Pharmaceuticals Inc [ABOS] rating to a Buy in a research note published on June 17, 2025; the price target was $4. A number of analysts have revised their coverage, including Citigroup’s analysts, who began to cover the stock in late July with a ‘”a Buy”‘ rating. Deutsche Bank began covering ABOS with “Buy” recommendation on December 12, 2023.
Price Performance Review of ABOS
On Tuesday, Acumen Pharmaceuticals Inc [NASDAQ:ABOS] saw its stock jump 7.02% to $1.22. Over the last five days, the stock has gained 3.39%. Acumen Pharmaceuticals Inc shares have fallen nearly -29.07% since the year began. Nevertheless, the stocks have fallen -53.79% over the past one year. While a 52-week high of $3.60 was reached on 01/06/25, a 52-week low of $0.86 was recorded on 04/21/25.
Levels Of Support And Resistance For ABOS Stock
The 24-hour chart illustrates a support level at 1.1633, which if violated will result in even more drops to 1.1067. On the upside, there is a resistance level at 1.2633. A further resistance level may holdings at 1.3067.
The most recent change occurred on May 18, 2023 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $13 price target.
